Despite significant improvements in pediatric brain tumor therapy and outcome, too many children still die of disease, and too many survivors experience significant sequelae as a result of conventional therapies. The molecular characterization of pediatric brain tumors has afforded tremendous insight into the basic biology and clinical management of these deadly childhood diseases. Genomic, epigenomic, and transcriptional profiling have facilitated the identification of significant heterogeneity among previously uniform disease entities. In particular, DNA methylation profiling has emerged as a robust tool for identifying key disease-specific subgroups that can exhibit distinct clinical outcomes. These approaches, which also complement classic histologic techniques, can suggest key mechanistic underpinnings of tumorigenesis and open the door for better informed and more tailored therapy. By leveraging the results of large-scale classifications of disease cohorts, novel driver mutations and pathways can be uncovered, enabling the generation of faithful animal models, promoting targeted drug design, informing developmental biology, and ultimately translating into improved clinical management. In this review, progress in the epigenetic classification of common malignant pediatric brain tumors, namely medulloblastoma, ependymoma, high-grade glioma, atypical teratoid/rhabdoid tumor, and central nervous system embryonal tumors, will be discussed, and the potential role of DNA methylation profiling as a frontline diagnostic modality will be emphasized. Cancer 2018;124:4168-4180.
INTRODUCTION
As the most common solid tumors in children, pediatric central nervous system (CNS) tumors represent an array of pathologically and molecularly diverse entities. 1, 2 The treatment of malignant CNS tumors in children presents a unique challenge given the exquisite susceptibility of the developing nervous system to damage from conventional treatment modalities of neurosurgery, craniospinal irradiation, and cytotoxic chemotherapy. Although refinement of these conventional modalities has improved survival in many cases, neurodevelopmental sequelae continue to confer significant morbidity to many children. 3, 4 Moreover, many patients still die of their disease despite these incremental advances. As such, improving the clinical management and ultimate long-term outcomes of these patients relies on uncovering subtle differences within disease categories that can refine the risk stratifications that dictate treatments and their intensities.
Given the vast diversity of pediatric CNS tumors, disease classification ultimately dictates and defines treatment. Traditional risk stratification schemes have relied on factors such as patient age, tumor histology, and metastatic status at the time of diagnosis to define treatment. Although these factors represent surrogate markers of complex underlying tumor biology and the subsequent natural history of the disease, they fail to recognize subtle molecular differences that now define prognosis. Similarly, although the inclusion of immunohistochemical (IHC) and cytogenetic markers have greatly refined prognostication, to the best of our knowledge these techniques are limited in their capacity to identify the numerous unique biologic subgroups that more advanced molecular techniques are uncovering. Driven by unbiased molecular profiling, the therapeutic implications of such subgroupings are immediate and major. By tailoring therapy based on risk of disease recurrence or responsiveness to conventional treatments, treatment escalation or dose reductions can
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Molecular approaches to study pediatric CNS tumors have flourished in the age of next-generation sequencing (NGS), providing a wealth of clinically and biologically significant insights into these deadly childhood diseases. By interrogating the molecular signatures of tumors, these methods have helped to reconcile disparate outcomes among previously uniform disease classifications, driving refinements in risk stratifications and therapeutic decision making. Among methods for molecular subgrouping, genome-wide methylation profiling has emerged as a powerful molecular tool with which to classify tumors. With the development of high-density arrays and improved bioinformatics pipelines, methylation classification of pediatric CNS tumors provides a robust, reproducible modality for classification with high concordance to subgroups initially identified by other molecular methods, such as gene expression profiling and genome sequencing. With its reasonable cost and favorable turnaround time, DNA methylation profiling represents a feasible implementation of molecular methods for diagnostic use and clinical protocol stratification.
In this review, we highlight the usefulness of genome-wide DNA methylation profiling in the subgrouping of pediatric brain tumors. After an overview of methodologies, a discussion of recently characterized entities with clinical implications is presented for medulloblastoma (MB), ependymoma (EPN), high-grade glioma, atypical teratoid/rhabdoid tumor (ATRT), and CNS embryonal tumors (formerly known as CNS primitive neuroectodermal tumors [PNETs] ). Finally, the rationale and proposal for the integration of methylation profiling into the clinical diagnostic pipeline is set forth.
Molecular Characterization by Genetic, Transcriptomic, and Now Epigenetic Analyses
Criteria for the classification of CNS tumors historically have been based on histology that relied on the anatomic location and morphologic similarity of tumors under light microscopy to specific cell types in the normal or developing brain. The advent of IHC and cytogenetic methods has allowed for further refinement of classification schemes by substratifying tumors based on expression patterns of lineage markers and the presence of specific structural abnormalities. Modern advances in molecular methods to interrogate tumors, including genomic, transcriptomic, and epigenomic characterizations, have provided deeper insights and highlighted tumor substructure, even among tumors that are indistinguishable by conventional methods. A more refined classification scheme layered with rich molecular data provides a significant step toward improving diagnostic reproducibility, improving risk stratification, informing the underlying mechanism of tumorigenesis, and facilitating the development of targeted therapeutic approaches for precision medicine.
Genomic analyses
Our understanding of the genetic landscape of pediatric CNS tumors has improved significantly with comprehensive genomic analyses, which have identified a significant number of recurrent, disease-specific abnormalities. These analyses have also highlighted key differences between pediatric CNS tumors and their adult counterparts while informing prognostication. Nevertheless, although genomic analysis of tumors by NGS is a powerful tool with which to interrogate the cancer genome, these methods still are costly and time-consuming, precluding their routine implementation into diagnostic and clinical pipelines. Moreover, a large percentage of tumors, particularly pediatric tumors, have been found to be devoid of pathognomonic genetic lesions or specific drivers that NGS uncovers. Rather, for many pediatric entities, epigenetic mechanisms are believed to be contributing to tumor etiology. 5 
Transcriptomic profiling
Transcriptomic analyses have contributed significantly to the subclassification of pediatric CNS tumors by identifying molecular derangements that are not evident at the genetic level. Disruptions of key developmental pathways and cellular processes have been identified by gene expression signatures, allowing for insights into the cell of origin and the development of therapies targeted to combat specifically deranged pathways. 6, 7 Profiling of large disease cohorts has uncovered the convergence of some diseases on altered canonical signaling pathways that may represent avenues of novel therapeutic intervention.
Although an extremely powerful tool in the subclassification of pediatric CNS tumors, several features have prevented the widespread adoption of transcriptomic analyses into clinical workflows. The majority of anatomic pathology laboratories routinely collect formalin-fixed, paraffin-embedded (FFPE) tissue for diagnostic purposes, whereas transcriptomic analysis has historically relied largely on the availability of frozen tissue to gather
Cancer November 1, 2018 high-quality RNA for array or NGS methods. The use of fresh frozen tissue rather than FFPE tissue invokes significant demands in terms of resources and added cost for proper tissue cryopreservation and storage. Furthermore, reliance on fresh frozen tissue has prevented the use of the large retrospective repositories of CNS tumors available in FFPE blocks or slides. More modern techniques have emerged for the recovery and restoration of RNA from FFPE material. 8 Despite these advances, fresh frozen tissue remains the gold standard for transcriptomic analysis, and the relative stability and versatility of DNA compared with RNA make DNA-based platforms more attractive for guiding clinical decision making.
DNA methylation profiling
In addition to genomic and transcriptomic approaches, epigenomics has emerged as a central focus in tumor biology. Epigenetic mechanisms regulate gene activity in precise spatiotemporal programs during development. Of these mechanisms, DNA methylation and histone tail modification have been characterized extensively. Distributed in a biased manner throughout the human genome, CpG islands often are located in gene promoters and function as key regulators of gene expression. 9 The cytosine bases in CpG islands undergo methylation to 5-methylcytosine through the action of DNA methyltransferases. Such covalent modification not only prevents accessibility of transcription factors to DNA but also leads to the recruitment of other chromatin modifiers that can lead to the formation of heterochromatin through changes in histone modifications. 10 In patients with cancer, aberrant patterns of DNA methylation can lead to the transcriptional inactivation of tumor suppressors. 11 Conversely, decreased levels of methylation at oncogenes can drive tumorigenesis. 12 The epigenetic crosstalk between DNA methylation and histone modification also suggests the role of aberrant chromatin modulation in the development of cancer. Failure of transcriptional programs for proper cellular differentiation during development therefore can lead to the inappropriate persistence of a proliferative progenitor-like cell population. Furthermore, patterns of DNA methylation and histone posttranslational modification may provide indirect assessment of developmental origins.
Methods for detecting cytosine modifications hinge on the treatment of DNA with bisulfite, which converts cytosine to uracil while not affecting 5-methylcytosine. 13 At the time of bisulfite treatment, DNA thus retains only methylated cytosine, allowing single-nucleotide resolution of methylation status (Fig. 1) . With a priori targets, methylation-specific polymerase chain reaction can be used to interrogate specific genomic loci whereas NGS methods can cover much larger regions of the genome without prior knowledge of specific targets. Despite its cost, whole-genome bisulfite sequencing can provide genome-wide, single-nucleotide methylation patterns. Array-based methods have evolved to include >850,000 CpG dinucleotides throughout the human genome.
14 As rapid, cost-effective methods for genome-wide coverage of methylation patterns mature, these data provide crucial insights into the epigenetic landscape of cancer.
Array-based assays for DNA methylation, such as the Illumina Infinium Human BeadChip arrays (450K and EPIC; Illumina Inc, San Diego, California), have certain characteristics rendering them amenable to use within the clinical environment. First, because these assays use DNA and query a relatively stable epigenetic mark, the issues of degradation and sample quality that plague transcript-based assays are avoided. In addition, comparable performance on FFPE and frozen tumor samples facilitates the use of archived tumor samples. The relatively low DNA input required for these assays (approximately 250 ng) typically can be obtained from <5 unstained FFPE sections. Because fixed tissue can be used, the isolation of tumor from the surrounding normal tissue can be accomplished by macrodissection of unstained sections or core needle biopsy of tissue blocks. It is important to note that these assays also can be performed and analyzed within one week, which is a reasonable timeframe for diagnostic implementation and use in the clinic (Fig. 1 ).
In parallel with methodological advances in interrogating the methylation landscape in biological samples, bioinformatics pipelines and classifiers have been developed to process the raw data into biologically and clinically applicable outputs. 15, 16 These computational methods use statistical tests and algorithms to make class predictions. Ensemble methods, such as random forest analyses, use the combinatorial power of many decision trees to improve predictive accuracy. 17 With the generation of larger and more numerous training reference data sets with well-annotated metadata, many of these classifiers have the potential to exploit advanced machine-learning techniques to optimize predictions of not only tumor class assignment but also clinical behavior or therapeutic response. The following discussion exemplifies how DNA methylation profiling can and will benefit the management of patients with pediatric CNS tumors.
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Medulloblastoma Medulloblastoma (MB) is the most common CNS embryonal tumor, with a cure rate of approximately 70%. [18] [19] [20] Standard treatment consists of maximal surgical resection, craniospinal irradiation, and adjuvant chemotherapy. Traditional risk stratification is based on age, extent of surgical resection, evidence of metastasis, and histological variants. 21 The prognosis for patients with high-risk disease remains suboptimal, and survivors from all risk groups often experience debilitating long-term morbidities. 22 Research within the past decade has revealed clinically relevant molecular heterogeneity within MB, thereby setting the stage for similar work to be performed in other pediatric and adult CNS tumors. 23, 24 Molecular subgrouping of MB was integrated into the 2016 update to the World Health Organization (WHO) classification of tumors of the CNS and currently is being used to stratify patients in prospective clinical trials. 25, 26 Data from transcriptomic analysis of multi-institutional MB cohorts led to the consensus classification. Unsupervised hierarchical clustering on expression arrays noted the disease split into 4 subgroups (named WNT, sonic hedgehog [SHH], group 3, and group 4), each with distinct patient-related characteristics, somatic genetic alterations, upregulated signaling pathways, and clinical course. 23, 24, [27] [28] [29] [30] [31] Patients with WNT subgroup MB were found to respond exceptionally well to conventional treatment modalities, with nearly uniform overall survival noted even across treatment regimens of varying intensity. Conversely, patients with group 3 MB tended to do poorly, with an overall survival rate of approximately 50% to 60%, whereas patients with SHH and group 4 With the ability to use formalin-fixed, paraffin-embedded (FFPE) or frozen tissue as input, the generation of DNA methylation data using array-based technologies can be accomplished in a timeline feasible for clinical implementation. In addition to class prediction outputs, DNA methylation data can provide robust copy number information while also facilitating powerful exploratory analyses that eventually could feedback into the core clinical pipeline. QC indicates quality control.
Cancer November 1, 2018 tumors had intermediate survival outcomes (70%-80%). Thus, by subgrouping the disease, it became conceivable to propose dose de-escalation strategies for certain patients carrying disease with a good prognosis (ie, WNT) to reduce treatment-related morbidity without compromising outcomes. Furthermore, subgroup stratification facilitated the identification of certain patients with very poor outcomes, particularly those with group 3 tumors with metastasis at the time of diagnosis.
Despite these groundbreaking discoveries, the routine application of transcriptomic methods carried practical issues, as mentioned previously. Hence, the immediate translation of these findings into the clinic was stunted, leading to a search for alternative platforms. 32 An RNA-based NanoString method (NanoString Technologies Inc, Seattle, Washington) and the use of IHC stains emerged as alternative strategies for the translation of the transcriptomic findings. To the best of our knowledge, NanoString has been used at a few centers but has failed to secure widespread acceptance. Meanwhile, the use of IHC stains to beta-catenin, yes-associated protein 1 (YAP1), and GAB1 enabled pathologists to rapidly recognize and distinguish WNT and SHH MBs from non-WNT/non-SHH MB using standard histopathological techniques. Nonetheless, this method has been difficult to standardize across all centers and to the best of our knowledge does not distinguish group 3 from group 4 tumors. 33 Conversely, methylation profiling faithfully recapitulates the 4 transcriptomic MB subgroups, even with a limited quantity of DNA from readily available FFPE material. 34 Comparison between the RNA-based NanoString method and methylation profiling demonstrated the superiority of the latter both in terms of subgroup assignment and the ability to identify tumors with alternative diagnoses. 35 Furthermore, methylation profiling also allows for subclassification or "subtyping" within the 4 subgroups, a characteristic that has proven to be particularly important for describing clinical and molecular heterogeneity within each of the non-WNT subgroups (Figs. 2 and 3) . 15, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Recent publications have shown that SHH exhibits significant clinical heterogeneity according to patient age at the time of diagnosis (infants, children, or adults) as well as somatic genetic alterations Cancer November 1, 2018 carried. 51 Although PTCH1 mutations are evenly distributed among the 3 age groups, infants often carry SUFU mutations; tumors from children are more likely to be TP53 mutated and GLI2 amplified; and SHH subgroup MBs in adults characteristically are enriched with SMO, DDX3X, and TERT promotor mutations. It is important to note that the survival outcome is different for each of these SHH subtypes. Fittingly, methylation profiling on large reference data sets, such as MolecularNeuropathology 2.0, which was developed at the German Cancer Research Center, can reproducibly and systematically recognize differences within the methylomes of SHH tumors that distinguish infant SHH MB from childhood or adult SHH MB (see MB, SHH, INF vs MB, SHH, CHL/AD in Fig. 2) . 15 Furthermore, new evidence has demonstrated that methylation profiling of infant SHH MB can detect low-risk and high-risk groups within infants in this tumor subgroup. 37, 52 Akin to the intertumoral heterogeneity observed within SHH MB, similar observations have been described among group 3 and group 4 MB. Definitively distinguishing group 3 from group 4 MB represents a challenge because of the now accepted inherent molecular overlap between the 2 groups that precludes complete separation. However, methylation profiling has facilitated the subtyping of consensus group 3 and group 4 tumors, thereby confirming their close molecular relationship (Fig. 2) . 15 Such identification of molecular overlap among consensus group 3 and group 4 tumors has led to their recent restructuring into at least 4 and as many as 
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Cancer November 1, 2018 8 subtypes in a series of recently published articles. [36] [37] [38] Despite a current lack of subtype consensus among these studies, common themes are emerging. The existence of a group 3 signature enriched with tumors harboring MYC amplification is irrefutable. Similarly, group 4 methylome signatures identify a set of MBs that contain recurrent chromatin remodeling aberrations. Finally, a mixed group 3/4 signature appears to be emerging that captures both group 3 and group 4 MBs harboring GFI1 overexpression with OTX2 copy number gain. Overlay of cytogenetic data onto these analyses has highlighted the broad distribution of abnormalities, such as 7q gain, 8p loss, and isochromosome 17q, spanning the group 3/4 continuum. Nonetheless, the next step is to determine how applicable and relevant these new categories are from a clinical perspective.
Methylation profiling thus has augmented the discovery of clinically informative heterogeneity. The application of this test to readily available samples with minimal processing along with the rapid turnaround time makes this an ideal platform for the development of a molecularly driven, risk-stratified clinical trial design with an eye toward targeted therapeutics and therapy de-escalation. Therefore, methylation profiling has appeal as a practical adjunct for subgroup assignment in patients with MB for prognostication and treatment stratification. Nonetheless, consensus subtype assignments based on methylation profiling must be established.
Atypical Teratoid/Rhabdoid Tumor
ATRT is an aggressive embryonal tumor of infancy and young childhood, characterized by abnormalities in SWI/ SNF (SWItch/Sucrose Non-Fermentable) complex genes leading to loss of INI1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1 [SMARCB1]) or, rarely, BRG1 (SWI/SNFrelated, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 [SMARCA4]) protein expression. 53, 54 Prognosis is exceptionally poor and toxicities resulting from conventional therapy in very young patients are significant. [55] [56] [57] [58] Attempts to mitigate such a malignant disease course will depend on our ability to gain a deeper understanding of ATRT biology and the molecular basis of the disease. SMARCB1 is a core component of the SWI/SNF chromatin-remodeling complex, which plays a crucial role in tumor suppression and has been implicated in the pathogenesis of numerous cancers. 59, 60 Whole-exome sequencing studies of rhabdoid tumors have shown that recurrent genetic alterations other than those in SMARCB1/SMARCA4 are surprisingly scarce, prompting the evaluation of noncoding regions and the epigenome. 40, 61 Two recent studies of ATRT based on methylation profiling have uncovered heterogeneity within what previously had been considered a single entity. Methylation profiling of 192 ATRTs and unsupervised clustering yielded 3 distinct subgroups (TYR, SHH, and MYC), supported by gene expression data (Figs. 2 and 3) . 15, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] ATRTs of the TYR subgroup occurred predominantly in patients aged <1 year and were more likely to be infratentorial. Expression data featured overexpression of melanosomal markers and genes involved in ciliogenesis. TYR, encoding tyrosinase, appeared to be a sensitive and specific biomarker for this subgroup. The ATRT-SHH subgroup comprised tumors located both supratentorially and infratentorially in patients aged <6 years with upregulation of SHH and NOTCH signaling. In ATRTs in the MYC subgroup, in which MYC overexpression was prevalent, disease often developed supratentorially and in patients aged ≥6 years. Torchia et al performed integrated genomic, transcriptomic, and methylomic analysis on another cohort of 191 primary ATRTs. 41 Three epigenetic subgroups, groups 1, 2A, and 2B, again were defined using DNA methylation arrays. Group 1 tumors predominantly were supratentorial; patients had a median age at diagnosis of 2 years and the tumors exhibited recurrent chromosome 14 gains and chromosome 19 losses and had SMARCB1 loss due to focal or subgenic alterations. Group 2A tumors predominantly were infratentorial; patients had a median age at diagnosis of 1 year and tumors genomically were bland. Group 2B included tumors arising from various locations; the majority of patients were aged >3 years and tumors had more focal genomic alterations across multiple chromosomes and SMARCB1 loss resulting from large deletions that encompassed additional genes on chromosome 22. These subgroups exhibited distinct methylation and expression patterns associated with lineage and developmental signaling genes.
With the lack of obvious concordance between the 2 subgrouping schemes of ATRT, a dire need to reach consensus with regard to subgrouping and nomenclature exists. However, once again, the usefulness of methylation profiling in identifying heterogeneity that corresponds with other characteristics such as tumor location, patient age at diagnosis, and patterns of molecular aberrations is apparent. Nonetheless, uncovering correlations between ATRT epigenetic subgroups and patient survival along with translations into direct clinical applicability are outstanding tasks. It is possible that patient
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CNS Embryonal Tumors (Formerly PNET)
A keen example of how DNA methylation profiling has revolutionized the understanding of and approach to pediatric brain tumors has come through the study of what previously was known as PNET (CNS PNET). 39 CNS PNET has long represented a diagnostic challenge due to its lack of specific morphological features and molecular markers. Distinguishing CNS PNET from histologic mimics such as high-grade glioma carries important clinical implications because patients with CNS PNET often are prescribed craniospinal rather than local radiotherapy. Historically, this embryonal tumor of childhood has been managed with the therapy used for MB based on the assumption that CNS PNETs represent a supratentorial equivalent of the infratentorially located MB. 64 Recent work has suggested such a framing of CNS PNET is incorrect. In a large collaborative study, a total of 323 tumors institutionally diagnosed as CNS PNET were compared with 211 reference samples by unsupervised clustering of their DNA methylation profiles. 39 Unexpectedly, approximately 61% of the cases diagnosed as CNS PNET clustered with other well-defined entities, including high-grade glioma (MYCN-amplified, receptor tyrosine kinases [RTK]-amplified, isocitrate dehydrogenase 1 [IDH]-mutant, and H3G34R/V-mutant glioma), H3K27M-mutant diffuse midline glioma, embryonal tumor with multilayered rosettes, EPN, ATRT, MB, pineal tumors, Ewing sarcoma, and choroid plexus carcinoma. Such reclassification was confirmed by orthogonal validation in the majority of cases. Of the remaining tumors diagnosed as CNS PNET, approximately 24% formed 4 distinct clusters. These newly described clusters were characterized by distinct genomic drivers as well as clinicopathologic findings and were designated as CNS neuroblastoma with forkhead box P2 (FOXR2) activation (CNS NB, FOXR2), CNS Ewing sarcoma family tumor with capicua transcriptional repressor (CIC) alteration (CNS EFT, CIC), CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET, MN1), and CNS high-grade neuroepithelial tumor with BCL6 corepressor (BCOR) alteration (CNS HGNET, BCOR) (Figs.   2 and 3) . 15, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Of the new groups, only the CNS NB, FOXR2 group met the classic histologic criteria for CNS PNET. Methylation profiling thus defined unknown subgroups within CNS PNETs and facilitated the recognition of histological features within these novel entities. Acknowledging the difficulty in diagnosis and the frequency of misclassification, CNS PNET was eliminated as a diagnostic entity from the WHO 2016 classification of CNS tumors. 25 Future studies must address the clinical behavior of these new tumor entities in addition to identifying appropriate treatment modalities and regimens for these novel groups. The traditional treatment paradigms for highgrade pediatric brain tumors also may require re-evaluation. Early work has begun to address these questions. The CNS PNET arm of the Children's Oncology Group ACNS0332 trial closed prematurely with the expectation that such newly introduced heterogeneity now would undermine the statistical power assumed in the study. Indeed, of the 31 nonpineal CNS PNETs with tissue available, 22 (71%) were reclassified as high-grade glioma (18 cases), ATRT (2 cases), and EPN (2 cases). 65 Patients with molecularly classified high-grade glioma had 5-year event-free and overall survival rates of 5.6% and 12%, respectively, compared with 62.8% and 78.5%, respectively, in those with molecularly classified embryonal tumors. Data regarding the clinical course of some newly defined entities are emerging, but to our knowledge remain anecdotal.
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Ependymoma EPN is the third most common CNS tumor of childhood after glioma and MB. 69 The standard of care consists of maximal surgical resection and adjuvant radiotherapy, whereas the role of chemotherapy continues to be investigated in ongoing trials. 70 Predictors of an inferior outcome include an infratentorial location of the primary tumor, residual disease after surgical resection, young age at the time of diagnosis, and management without adjuvant radiotherapy. Tumor grading (WHO grade 2 vs WHO grade 3) has been shown to demonstrate high interobserver variability along with a questionable association with patient outcome and is no longer recommended to dictate treatment options. [71] [72] [73] Tumors from different anatomical compartments have indistinguishable histological features, and it was not until a decade ago that the application of gene expression arrays illustrated distinct profiles among them. 74 Subsequent whole-genome and epigenome analyses have characterized recurrent fusion between v-rel avian reticuloendotheliosis viral oncogene
Cancer November 1, 2018 homolog A (RELA) and chromosome 11 open reading frame 95 (C11orf95) in > 70% of supratentorial EPNs, a new entity in the latest WHO classification, while also identifying 2 molecular subgroups with prognostic significance among posterior fossa EPN. [42] [43] [44] 75 Methylation profiling of 500 EPNs from various anatomical locations and patients of various ages have consolidated earlier findings, allocating EPN into 9 subgroups (Figs. 2 and 3) . 15, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Three of the molecular subgroups encompass WHO grade 1 subependymoma, each separated by the 3 anatomical compartments in which these are found: supratentorial subependymoma (ST-SE), posterior fossa subependymoma (PF-SE), and spinal subependymoma (SP-SE). Nonsubependymoma supratentorial tumors were classified into supratentorial EPN with RELA fusion (ST-EPN-RELA) and supratentorial EPN with YAP1 fusion (ST-EPN-YAP1). Likewise, nonsubependymoma posterior fossa tumors were classified into posterior fossa EPN group A (PF-EPN-A) and posterior fossa EPN group B (PF-EPN-B). Finally, spinal nonsubependymomas were classified into groups enriched in WHO grade 1 myxopapillary EPN (SP-MPE) and WHO grade 2 EPN (SP-EPN). 45 ST-EPN-RELA represented approximately two-thirds of the nonsubependymoma tumors in the supratentorial compartment, with a median patient age at diagnosis of 8 years and approximately 75% of cases being assigned WHO grade 3. The less common ST-EPN-YAP1 was characterized by a younger patient age at diagnosis (median age at diagnosis, 1.4 years) and a better outcome. Of the posterior fossa EPNs, PF-EPN-A was associated with a younger age at diagnosis (median age, 3 years), laterally located tumors, a balanced genome, and a worse prognosis, particularly with an increased risk of metastatic disease recurrence. 42, 45, 75 Patients with PF-EPN-B were older children and adults (median age, 30 years), often with centrally located tumors and a higher degree of genomic instability. Gain of chromosome 1q, despite being observed in PF-EPN-A, PF-EPN-B, and ST-EPN-RELA tumors, only manifested itself as poor prognostic marker in PF-EPN-A tumors. 45 The clinical value of molecular subgrouping in posterior fossa EPN subsequently was validated in a large retrospective study consisting of 820 patients from 4 independent cohorts. 76 Multivariate analysis accounting for molecular subgrouping, age, sex, extent of surgery, and adjuvant therapy revealed molecular subgrouping to be the most powerful predictor of progression-free and overall survival. 76 In addition to confirming the poor prognosis in patients with PF-EPN-A, it was shown that a percentage of patients with PF-EPN-B could be cured by macroscopic total surgical resection alone. Therefore, these findings are prompting the development of new strategies in upcoming clinical trials, in which therapy is expected to be risk stratified by molecular classification.
71,73

High-Grade Glioma (Including Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme)
High-grade glioma accounts for approximately 15% to 20% of pediatric CNS tumors and is largely incurable, with a median survival ranging between 10 and 18 months. 50 The current standard of care for patients with high-grade glioma involves maximal safe surgical resection, which often is incomplete due to the tumor location and its infiltrative nature, followed by adjuvant focal radiotherapy. To the best of our knowledge, therapeutic interventions in pediatric high-grade glioma, including those extrapolated from adult studies, have been disappointing to date. 77, 78 Clinical and molecular studies in high-grade glioma across age groups suggest that pediatric and adult tumors have distinct developmental origins and disease biology. 79 Driver mutations in genes encoding histones H3.1 and H3.3 now characterize pediatric glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG). 80, 81 Sturm et al have since identified 6 epigenetic subgroups (K27, G34, IDH, RTK I, RTK II, and mesenchymal). 46 These findings were validated and expanded upon by methylation profiling in larger cohorts of patients with pediatric high-grade glioma. 48, 49 Hierarchical clustering of 202 pediatric cases resulted in 4 subsets: 1) H3.3/H3.1K27M-mutated; 2) H3.3G34R-mutated; 3) IDH1-mutated; and 4) H3/IDH-wild type (wt) cases; each was characterized by unique clinical and molecular profiles, in keeping with the previous study (Figs. 2 and 3) . 15, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] H3.3/H3.1K27M-mutated tumors were the most common tumors and had a dismal prognosis. They occurred in younger children, were predominantly midline, metastasized in approximately one-half of the cases, and rarely displayed O 6 -methylguanine-DNA methyltransferase (MGMT) promotor methylation. The devastating entity of DIPG (also known as brainstem glioma) fell into this category. The H3.3G34R-mutated and IDH1-mutated tumors had better outcomes, occurred in older patients, were often located in the hemispheres, and were enriched with MGMT promotor methylation. Unlike
Cancer November 1, 2018 their IDH1-mutated adult counterparts, there was no evidence that these pediatric GBMs transformed from precursor lesions. 82 Within the H3/IDH-wt tumors, 3 clearly defined epigenetic clusters with respective oncogene amplification, namely pedGBM-MYCN, pedGBM-RTK1 (enriched for PDGRFA amplification), and pedGBM-RTK2 (enriched for EGFR amplification), were recognized. 46, 49 Multivariate analysis identified methylation profile-derived molecular subtype as the only significant prognostic factor. Additional analysis of cases that fell into this category, prompted by the identification of extended survival in some patients, revealed samples that molecularly resembled low-grade glioma (LGG) and pleomorphic xanthoastrocytoma (PXA). The LGG-like tumors were diagnosed for the most part in young children (aged < 3 years) and had a better prognosis (3-year overall survival rate of 91%), thereby supporting the long-held observation that high-grade gliomas in infants respond better to treatment. 83, 84 PXA-like tumors had the highest frequency of BRAF V600E and an intermediate prognosis.
It is interesting to note that histological review of LGGlike and PXA-like tumors confirmed the typical appearance of high-grade glioma in > 80% of the cases, thereby highlighting the usefulness of methylation profiling in accurately identifying these subgroups in the clinical setting. 48 The molecular landscape of pediatric high-grade glioma was most recently consolidated by the integrated molecular analysis of >1000 cases. 50 Although the Cancer November 1, 2018 majority of these entities are universally fatal, it has become apparent that molecular characteristics are important. Methylation profiling provides valuable prognostic information by subgroup definition, providing an opportunity to better counsel families and to focus efforts against unique molecular aberrations.
Integration of Methylation Profiling With FirstLine Diagnostics in Pediatric CNS Tumors
Despite greatly enhancing our understanding of and ability to classify pediatric CNS tumors, DNA methylation profiling remains primarily a research rather than a clinical tool. However, given the profound effect this modality has had on expanding and defining the molecular landscape of pediatric CNS tumors and its relative ease of application, more widespread adoption in the clinical setting appears inevitable. Its potential as an aid to clinical diagnosis, treatment decision making, and study trial design appears boundless (Fig. 4) . Nonetheless, certain limitations and caveats must be acknowledged before blindly accepting methylation profiling into the clinic. The introduction of methylation-based methods does not suggest that more traditional approaches will or should be completely supplanted. Moreover, similar to other tools used in neuropathology, such as IHC, fluorescence in situ hybridization, and NGS, methylation profiling needs to remain an instrument that assists in diagnosis rather than declaring it. Classification by methylation profiling may be impossible in cases with insufficient biopsy tissue or poor DNA yields. Hypocellular lowgrade tumors or those with stromal contamination may not contain sufficient tumoral DNA to yield an accurate classification, as is the case for some diffuse astrocytomas. 85 Even in cases with adequate material, some tumors may remain unclassifiable by methylation, as observed in a recent comprehensive cohort with 82 methylation classes in which approximately 12% of samples scored too poorly for confident classification. 15 The reference cohort used to train the classification model may not contain sufficient samples from a particular rare entity. Because classifiers often are designed to generate a best fit for a given input, incorrect grouping may occur in such cases. Continued expansion of reference cohorts and the inclusion of uncommon as well as novel entities would be required to improve the versatility and accuracy in classification over time. Further work also will be needed to validate DNA methylation profiling for classifying LGG, due to frequent difficulty in class assignment. Furthermore, intracranial (nongerminomatous) germ cell tumors will require careful evaluation by this method because of inherent variability in the contribution and composition of teratomatous elements, the often substantial stromal contribution to the tumor, and the often focal nature of malignant germ cell tumor elements. 85, 86 For rare tumor types or tumors that present with challenging histomorphology, methylation-based approaches will allow for better standardization of diagnoses across centers. As discussed, tumor subgrouping and subtyping based on methylation profiling are expected to improve prognostication, risk assignment, and treatment stratification. MB, EPN, and infant GBM represent key examples in which molecular subgrouping has shown remarkable proficiency at predicting treatment outcome in large retrospective molecular cohorts. 48, 71, 87 Figure 4 depicts our vision of how DNA methylation profiling may be applied to clinical diagnoses. In this way methylation profiling will not supplant clinical acumen, but rather augment current practices. Clinicoradiological and histopathological features will continue to remain core to the classification of pediatric CNS tumors. Moreover we envision that classification using methylation-based methods will improve histomorphologic methods of classification by empowering pathologists to recognize previously unappreciated patterns that are associated with specific molecular subgroups and to better develop orthogonal biomarkers for novel entities or cases in which tissue is limited. Even in the case of the widespread adoption of methylation profiling, the need to produce and assess histologic sections remains paramount, particularly, but not limited to, quality control, assessing tumor grade, and clinical stage.
CONCLUSIONS
DNA methylation profiling brings a highly robust and accurate molecular characterization system to abundant and accessible pathology samples. As a clinically feasible tool, the integration of DNA methylation profiling into the diagnosis and management of children with brain tumors represents an obtainable goal with which to assist in the diagnosis and improve clinical trial design. Coupled with histopathologic, genetic, and transcriptomic analyses, epigenetic profiling also will result in fundamental advances in the understanding of basic tumor biology.
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